Biotron: Completes phase two HIV-1 trial recruitment

Biotron Completes phase two HIV-1 trial recruitment

• Biotron (BIT) completes recruitment of the phase two HIV-1 clinical trial with its lead antiviral drug, BIT225
• The study will be carried out in people infected with HIV-1 who have achieved partial immune reconstitution despite treatment
• Participants will receive 200 milligrams of BIT225 daily over 12 weeks to determine any changes in immune, inflammation, viral and immune activation markers
• The trial is scheduled to be completed in January 2023 with preliminary results expected in mid-2023
• The company is up 4.35 per cent on the market with shares trading at 4.8 cents at 2:15 pm AEDT